Exercise Intervention Targeting Hip Strengthening Compared to Usual Care in Patients Undergoing Revision Hip Replacement
Condition(s) studied
Investigational drug(s) / intervention(s)
Exercise Intervention Targeting Hip Strengthening: An initial 16-week exercise intervention of 45 minutes of training 3 times a week in the patient's own home or at a rehabilitation center. Patients will be instructed by a physiotherapist during the first 3 sessions, in order to be able to perform the exercises at home. Subsequently, there are physiotherapist-supervised sessions once every second week. The delivery of the supervised sessions is based on the patient's preferences, either by physical attendance or remotely in the patient's home. The intervention will consist of 4 exercises adapted from the NEMEX program targeting lower extremity muscle strength, stability, postural function, and postural orientation. Progression is made when an exercise is performed with good sensorimotor control and good performance quality and with minimal exertion and adequate movement control. Progression is primarily provided by 3 levels of difficulty and secondly by varying the number of repetitions or where possible, by increasing the weight load.
Usual Care: The intervention will consist of a rehabilitation intervention corresponding to standard care in the participating municipalities (i.e. content and duration of intervention). The intervention will be delivered individually or as group training, based on a clinical assessment of the individual patients' needs. The intervention can be supported by home-based exercises following instruction from a physiotherapist, supplemented by the provision of written information or access to a virtual training program. The intervention occurs in either the rehabilitation center's gym or the patient's home. The training sessions may consist of some of the following parameters: Strength training, stretching, functional training e.g. walking and stair climbing, stability training, balance training, endurance training, and gait correction.
Study summary
There is sparse evidence on revision total hip replacement (THR), regarding the effectiveness on pain and function, and no consensus exists on optimal rehabilitation after revision THR. Further, patients undergoing revision THR achieve worse clinical outcomes on hip pain and function compared to patients undergoing primary THR. The primary aim of this randomized controlled trial is to compare the clinical effectiveness of a partly tele-delivered exercise intervention targeting hip strengthening with the standard community-based rehabilitation (usual care) in patients undergoing revision THR. The investigators will test the hypothesis that the exercise intervention targeting hip strengthening is superior to standard community-based rehabilitation in improving physical function measured with the 30-second Chair Stand Test at 16-week follow-up.
Eligibility
Primary outcome measure(s)
- Change in functional performance measured by the 30-seconds chair stand test — Measured at baseline, 16-week, and 12-month follow-up.
The 30-second chair stand test is a valid and reliable measure of lower-extremity muscle strength evaluating sit-to-stand function, which is limited in people undergoing hip replacement.
Trial sites (9)
| Facility | City | Region | Status |
|---|---|---|---|
| Aarhus University | Aarhus | Denmark | |
| Aarhus University Hospital | Aarhus N | Denmark | |
| Bispebjerg Hospital | Copenhagen | Denmark | |
| University Hospital, Gentofte, Copenhagen | Hellerup | Denmark | |
| Gødstrup Hospital | Herning | Denmark | |
| Odense University Hospital | Odense | Denmark | |
| Regional Hospital Silkeborg | Silkeborg | Denmark | |
| Vejle Hospital | Vejle | Denmark | |
| Regional Hospital Viborg | Viborg | Denmark |
More University of Aarhus trials in Denmark
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05657054 on ClinicalTrials.gov ↗ ← All trials in Denmark